Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution

Autor: Llucia Alos, F A Moreno, Joseph Malvehy, G Villacampa, Marcelo Sánchez, I Valduvieco, G R Ares, E Carcelero, M M Estébanez, R Rull, R Martin-Huertas, Cristina Teixidó, A.M. Arance Fernandez, C.M. Vila, Pedro Jares, H S Oberoi, P Dashti
Rok vydání: 2021
Předmět:
Zdroj: Clinical and Translational Oncology. 24:319-330
ISSN: 1699-3055
1699-048X
DOI: 10.1007/s12094-021-02692-9
Popis: We retrospectively analysed overall survival (OS) and potential predictive biomarkers of OS in patients with metastatic melanoma treated with ipilimumab plus nivolumab in a single institution. Electronic medical records of patients with advanced melanoma receiving ≥ 1 dose of a combined ipilimumab plus nivolumab regimen between March 3, 2016 and March 7, 2020 in a single institution, were reviewed. OS was analysed using the Kaplan–Meier method. Sub-group analyses were conducted to examine several endpoints according to relevant clinical, molecular and pathological variables using logistic and Cox models. Forty-four cases were reviewed, 38 (86.4%), of whom had cutaneous melanoma, 21 (47.7%) were BRAF mutant, 21 (47.7%) presented high lactate dehydrogenase (LDH) values, 23 (52.3%) had ≥ 3 disease sites, and 10 (22.7%) patients had brain metastases. The median follow-up was 37.7 months, and the median OS was 21.1 months (95% CI 8.2–NR). In the multivariate analysis, the OS was significantly longer in patients with an Eastern Cooperative Oncology Group (ECOG) score of 0, LDH ≤ upper limit of normal, absence of liver metastases and neutrophil-to-lymphocyte ratio (NLR)
Databáze: OpenAIRE
Externí odkaz: